• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiol Infect . SARS-CoV-2 seroepidemiology in paediatric population during Delta and Omicron predominance

tetano

Editor, Senior Moderator
Epidemiol Infect


. 2022 Oct 19;150:e177.
doi: 10.1017/S0950268822001601.
SARS-CoV-2 seroepidemiology in paediatric population during Delta and Omicron predominance


Filippos Filippatos[SUP] 1 [/SUP], Elizabeth-Barbara Tatsi[SUP] 2 [/SUP], Charilaos Dellis[SUP] 1 [/SUP], Dimitra-Maria Koukou[SUP] 1 [/SUP], Christos Papagiannopoulos[SUP] 3 [/SUP], Alexandra Margeli[SUP] 4 [/SUP], Tania Siahanidou[SUP] 3 [/SUP], Christina Kanaka-Gantenbein[SUP] 3 [/SUP], Vasiliki Syriopoulou[SUP] 1 [/SUP], Athanasios Michos[SUP] 1 [/SUP]



Affiliations

Abstract

Limited prospective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) data in children regarding the impact of Omicron variant in seropositivity have been reported. We investigated SARS-CoV-2 seropositivity in children between 1 September 2021 and 30 April 2022, representing Delta and Omicron predominance periods. Serum samples from children admitted to the major tertiary Greek paediatric hospital for any cause, except for COVID-19, were randomly collected and tested for SARS-CoV-2 natural infection antibodies against nucleocapsid antigen (Elecsys® Anti-SARS-CoV-2 reagent). A total of 506/1312 (38.6%) seropositive children (0-16 years) were detected (males: 261/506(51.6%); median age (IQR): 95.2 months(24-144)). Seropositivity rates (%) increased from Delta to Omicron period from 29.7% to 48.5% (P-value<0.0001). Seropositivity increased for all age groups, except for the age group of 0-1 year (P-value:0.914). The highest seropositivity rate was detected in April 2022 (52.6%) and reached 73.9% specifically for the age group 12-16 years. No significant differences were detected in seropositivity with respect to gender, origin, or hospitalisation status. Median (IQR) antibody titres were higher in the Omicron vs. Delta period in all age groups, especially in 12-16 years [32.2 COI (7-77.1) vs. 11.4 COI(2.8-50.2), P-value:0.009). During Omicron variant period increased SARS-CoV-2 seropositivity was detected in paediatric population, especially in adolescents, implicating either increased transmissibility or reinfection rates.

Keywords: COVID-19; Children; Omicron variant; SARS-CoV-2; seroepidemiology.
 
Back
Top Bottom